34 results
8-K
EX-99.1
ESPR
Esperion Therapeutics Inc.
27 Feb 24
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
7:23am
as appropriate.
Tendon Rupture: Bempedoic acid, a component of NEXLIZET and NEXLETOL, is associated with an increased risk of tendon rupture or injury. Tendon
8-K
EX-99.1
ESPR
Esperion Therapeutics Inc.
7 Nov 23
Esperion Reports Third Quarter 2023 Financial Results
7:30am
, a component of NEXLIZET and NEXLETOL, is associated with an increased risk of tendon rupture or injury. Tendon rupture occurred within weeks to months
8-K
EX-99.1
ESPR
Esperion Therapeutics Inc.
1 Aug 23
Esperion Reports Second Quarter 2023 Financial Results
7:07am
treatment with urate-lowering drugs as appropriate.
Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture or injury
8-K
EX-99.1
ESPR
Esperion Therapeutics Inc.
26 Jun 23
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
6:03am
with an increased risk of tendon rupture or injury. In clinical trials, tendon rupture occurred in 0.5% of patients treated with bempedoic acid versus 0% of patients
8-K
EX-99.1
8qrvotypxylm
9 May 23
Esperion Reports First Quarter 2023 Financial Results
7:22am
8-K
EX-99.1
plwrv
4 May 23
Other Events
9:26am
8-K
EX-99.2
q0vp7gppivu5n
4 May 23
Other Events
9:26am
8-K
EX-99.1
b3noz7 x61v4
27 Feb 20
Results of Operations and Financial Condition
7:30am
8-K
EX-99.1
abujcc
21 Feb 20
Other Events
12:00am
8-K
EX-99.1
rq3oulosmi7
8 May 18
Regulation FD Disclosure
7:41am